Conflict of Interest Reform: Greatest Impact May Be Committee Vacancy Rate
Executive Summary
FDA user fee reauthorization eliminates limits on waivers, which may ease the burden on FDA to fill open seats on its advisory committees. Vacancy rates have been as high as 24% in FY 2012.
You may also be interested in...
Conflicts Galore: Upcoming Accelerated Approval Cancer Panel Includes Many Industry Relationships
US FDA issued six conflict-of-interest waivers for the Oncologic Drugs Advisory Committee’s three-day panel to consider whether indications for three immunotherapies – Tecentriq, Keytruda and Opdivo – should be withdrawn after failed clinical outcomes studies.
Top US FDA Officials Continue To Lament Advisory Cmte. Recruitment Difficulties
Strict conflict of interest rules have hampered the agency's ability to fill advisory committee vacancies.
CDER Advisory Committee Staffing Improves, But Trouble Spots Remain
After years of widespread vacancies on advisory committees, the Food & Drug Administration appears to have tackled most of the problems. But there are a couple of significant outliers, most significantly the Dermatology & Ophthalmic Products Advisory Committee. Will changes in conflict of interest rules and a new recruitment effort help FDA find and retain advisory committee members?